Marina Pulido-Ruiz

Mrs. Marina Pulido-Ruiz

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2013 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
MPMarina Pulido-Ruiz
Marina Pulido-Ruiz
MGMeritxell García-Quintanilla
Meritxell García-Quintanilla
RMReyes Martín-Peña
Reyes Martín-Peña
JCJosé M. Cisneros
José M. Cisneros
MMMichael McConnell
Michael McConnell
Antimicrobial susceptibility testing is essential for guiding the treatment of many types of bacterial infections, especially in the current context of rising rates of antibiotic resistance. The most commonly employed methods rely on the detection of phenotypic resistance by measuring bacterial growth in the presence of the antibiotic being tested. Although these methods are highly sensitive for the detection of resistance, they require that the bacterial pathogen is isolated from the clinical sample before testing and must employ incubation times that are sufficient for differentiating resistant from susceptible isolates. Knowledge regarding the molecular determinants of antibiotic resistance has facilitated the development of novel approaches for the rapid detection of resistance in bacterial pathogens. PCR-based techniques, mass spectrometry, microarrays, microfluidics, cell lysis-based approaches and whole-genome sequencing have all demonstrated the ability to detect resistance in various bacterial species. However, it remains to be determined whether these methods can achieve sufficient sensitivity and specificity compared with standard phenotypic resistance testing to justify their use in routine clinical practice. In the present review, we discuss recent progress in the development of methods for rapid antimicrobial susceptibility testing and highlight the limitations of each approach that still remain be addressed.

17 January 2012 in Diabetes
Verified
Journal Article
Open access
PDF file
José María Moreno-NavarreteJosé María Moreno-Navarrete
José María Moreno-Navarrete
Victoria CatalánVictoria Catalán
Victoria Catalán
LWLauren Whyte
Lauren Whyte
ADAdenis Díaz-Arteaga
Adenis Díaz-Arteaga
RVRafael Vázquez-Martínez
Rafael Vázquez-Martínez
RNRuben Nogueiras
Ruben Nogueiras
GPR55 is a putative cannabinoid receptor, and l-α-lysophosphatidylinositol (LPI) is its only known endogenous ligand. We investigated 1) whether GPR55 is expressed in fat and liver; 2) the correlation of both GPR55 and LPI with several metabolic parameters; and 3) the actions of LPI on human adipocytes. We analyzed CB1, CB2, and GPR55 gene expression and circulating LPI levels in two independent cohorts of obese and lean subjects, with both normal or impaired glucose tolerance and type 2 diabetes. Ex vivo experiments were used to measure intracellular calcium and lipid accumulation. GPR55 levels were augmented in the adipose tissue of obese subjects and further so in obese patients with type 2 diabetes when compared with nonobese subjects. Visceral adipose tissue GPR55 correlated positively with weight, BMI, and percent fat mass, particularly in women. Hepatic GPR55 gene expression was similar in obese and type 2 diabetic subjects. Circulating LPI levels were increased in obese patients and correlated with fat percentage and BMI in women. LPI increased the expression of lipogenic genes in visceral adipose tissue explants and intracellular calcium in differentiated visceral adipocytes. These findings indicate that the LPI/GPR55 system is positively associated with obesity in humans.

1 March 2013 in Trends in Microbiology
Verified
Journal Article
Closed access
MGMeritxell García-Quintanilla
Meritxell García-Quintanilla
MPMarina Pulido-Ruiz
Marina Pulido-Ruiz
RLRafael López-Rojas
Rafael López-Rojas
JPJerónimo Pachón
Jerónimo Pachón
MMMichael McConnell
Michael McConnell

28 July 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MPMarina Pulido-Ruiz
Marina Pulido-Ruiz
ADAlberto Diaz-Ruiz
Alberto Diaz-Ruiz
YJYolanda Jimenez-Gomez
Yolanda Jimenez-Gomez
SGSocorro Garcia-Navarro
Socorro Garcia-Navarro
FGFrancisco Gracia-Navarro
Francisco Gracia-Navarro
MMMaria del Mar Malagón
Maria del Mar Malagón
Lipid droplets (LDs) are organelles that coordinate lipid storage and mobilization, both processes being especially important in cells specialized in managing fat, the adipocytes. Proteomic analyses of LDs have consistently identified the small GTPase Rab18 as a component of the LD coat. However, the specific contribution of Rab18 to adipocyte function remains to be elucidated. Herein, we have analyzed Rab18 expression, intracellular localization and function in relation to the metabolic status of adipocytes. We show that Rab18 production increases during adipogenic differentiation of 3T3-L1 cells. In addition, our data show that insulin induces, via phosphatidylinositol 3-kinase (PI3K), the recruitment of Rab18 to the surface of LDs. Furthermore, Rab18 overexpression increased basal lipogenesis and Rab18 silencing impaired the lipogenic response to insulin, thereby suggesting that this GTPase promotes fat accumulation in adipocytes. On the other hand, studies of the β-adrenergic receptor agonist isoproterenol confirmed and extended previous evidence for the participation of Rab18 in lipolysis. Together, our data support the view that Rab18 is a common mediator of lipolysis and lipogenesis and suggests that the endoplasmic reticulum (ER) is the link that enables Rab18 action on these two processes. Finally, we describe, for the first time, the presence of Rab18 in human adipose tissue, wherein the expression of this GTPase exhibits sex- and depot-specific differences and is correlated to obesity. Taken together, these findings indicate that Rab18 is involved in insulin-mediated lipogenesis, as well as in β-adrenergic-induced lipolysis, likely facilitating interaction of LDs with ER membranes and the exchange of lipids between these compartments. A role for Rab18 in the regulation of adipocyte biology under both normal and pathological conditions is proposed.

7 August 2012 in Diabetologia
Verified
Journal Article
Closed access
PDF file
ARAmaia Rodríguez
Amaia Rodríguez
Javier Gomez-AmbrosiJavier Gomez-Ambrosi
Javier Gomez-Ambrosi
Victoria CatalánVictoria Catalán
Victoria Catalán
FRFernando Rotellar
Fernando Rotellar
VVV. Valentí
V. Valentí
GFGema Frühbeck
Gema Frühbeck

1 June 2017 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
CHChristian M. Harding
Christian M. Harding
MPMarina Pulido-Ruiz
Marina Pulido-Ruiz
GVGisela Di Venanzio
Gisela Di Venanzio
RKRachel L. Kinsella
Rachel L. Kinsella
AWAndrew I. Webb
Andrew I. Webb
MFMario F. Feldman
Mario F. Feldman
Pathogenic Acinetobacter species, including Acinetobacter baumannii and Acinetobacter nosocomialis, are opportunistic human pathogens of increasing relevance worldwide. Although their mechanisms of drug resistance are well studied, the virulence factors that govern Acinetobacter pathogenesis are incompletely characterized. Here we define the complete secretome of A. nosocomialis strain M2 in minimal medium and demonstrate that pathogenic Acinetobacter species produce both a functional type I secretion system (T1SS) and a contact-dependent inhibition (CDI) system. Using bioinformatics, quantitative proteomics, and mutational analyses, we show that Acinetobacter uses its T1SS for exporting two putative T1SS effectors, an Repeats-in-Toxin (RTX)-serralysin-like toxin, and the biofilm-associated protein (Bap). Moreover, we found that mutation of any component of the T1SS system abrogated type VI secretion activity under nutrient-limited conditions, indicating a previously unrecognized cross-talk between these two systems. We also demonstrate that the Acinetobacter T1SS is required for biofilm formation. Last, we show that both A. nosocomialis and A. baumannii produce functioning CDI systems that mediate growth inhibition of sister cells lacking the cognate immunity protein. The Acinetobacter CDI systems are widely distributed across pathogenic Acinetobacter species, with many A. baumannii isolates harboring two distinct CDI systems. Collectively, these data demonstrate the power of differential, quantitative proteomics approaches to study secreted proteins, define the role of previously uncharacterized protein export systems, and observe cross-talk between secretion systems in the pathobiology of medically relevant Acinetobacter species.